Safety, Tolerability, and Efficacy of Oral Therapies for Relapsing-Remitting Multiple Sclerosis

被引：0

作者：

Jiwon Oh

Paul W. O’Connor

机构：

[1] Johns Hopkins University,Department of Neurology

[2] University of Toronto,St. Michael’s Hospital, Division of Neurology, Department of Medicine

来源：

CNS Drugs | 2013年 / 27卷

关键词：

Multiple Sclerosis; Multiple Sclerosis Patient; Progressive Multifocal Leukoencephalopathy; Natalizumab; Glatiramer Acetate;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

Treatment options for relapsing-remitting multiple sclerosis (RRMS) have been continuously expanding in recent years, and the emergence of a number of oral disease-modifying agents (DMAs) has significantly changed the landscape of therapeutic options for MS patients. Many of these oral DMAs have demonstrated satisfactory safety and tolerability profiles in clinical trial settings, but the long-term safety of these agents is an important concern. This review discusses salient points on the safety and clinical efficacy of the approved and emerging novel oral therapies in RRMS, including fingolimod, teriflunomide, dimethyl fumarate, laquinimod, and cladribine.

引用

页码：591 / 609

页数：18

共 50 条

[31] Efficacy and safety of natalizumab in children with highly active relapsing-remitting multiple sclerosis
Karageorgiou, Klimentini E.
Polyzoi, Maria
Tzitzika, Moira
Xatzi, Ioanna
Alexoudi, Athanasia
MULTIPLE SCLEROSIS, 2008, 14 : S51 - S51
[32] Relapsing-remitting multiple sclerosis
Flores, A
Ochoa, E
Zamora, S
Barrientos, UN
JOURNAL OF THE NEUROLOGICAL SCIENCES, 2003, 214 (1-2) : 110 - 110
[33] Safety of teriflunomide for the management of relapsing-remitting multiple sclerosis
Papadopoulou, Athina
Kappos, Ludwig
Sprenger, Till
EXPERT OPINION ON DRUG SAFETY, 2015, 14 (05) : 749 - 759
[34] Safety of tetanus vaccination in relapsing-remitting multiple sclerosis
De Keyser, J
INFECTION, 1998, 26 (05) : 319 - 319
[35] Real world efficacy and safety of teriflunomide in patients with relapsing-remitting multiple sclerosis
Boz, C.
Ozakbas, S.
Terzi, M.
Turkoglu, R.
Akman, G.
Efendi, H.
Akcali, A.
Tuncer, A.
Yuceyar, N.
Turan, O. F.
Soysal, A.
Koseoglu, M.
Balci, B. P.
Sevim, S.
Altintas, A.
Cilingir, V.
Demirkiran, M.
Kizilay, F.
Altunrende, B.
MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 327 - 328
[36] Safety and efficacy of ofatumumab in relapsing-remitting multiple sclerosis A phase 2 study
Sorensen, Per S.
Lisby, Steen
Grove, Richard
Derosier, Frederick
Shackelford, Steve
Havrdova, Eva
Drulovic, Jelena
Filippi, Massimo
NEUROLOGY, 2014, 82 (07) : 573 - 581
[37] An update on the safety of treating relapsing-remitting multiple sclerosis
Chisari, Clara G.
Toscano, Simona
D'Amico, Emanuele
Lo Fermo, Salvatore
Zanghi, Aurora
Arena, Sebastiano
Zappia, Mario
Patti, Francesco
EXPERT OPINION ON DRUG SAFETY, 2019, 18 (10) : 925 - 948
[38] Immunogenicity of alemtuzumab treatment for relapsing-remitting multiple sclerosis: no effect on efficacy or safety
Selmaj, K.
MULTIPLE SCLEROSIS, 2009, 15 (09): : S247 - S247
[39] THE EFFICACY OF AZATHIOPRINE IN RELAPSING-REMITTING MULTIPLE-SCLEROSIS
GOODKIN, DE
BAILLY, RC
TEETZEN, ML
HERTSGAARD, D
BEATTY, WW
NEUROLOGY, 1991, 41 (01) : 20 - 25
[40] Timing of high-efficacy disease modifying therapies for relapsing-remitting multiple sclerosis
Merkel, B.
Jokubaitis, V.
Spelman, T.
Horakova, D.
Havrdova, E.
Trojano, M.
Izquierdo, G.
Lugaresi, A.
Prat, A.
Girard, M.
Duquette, P.
Sola, P.
Ferraro, D.
Grammond, P.
Hupperts, R.
Bergamaschi, R.
Alroughani, R.
Boz, C.
Terzi, M.
Pucci, E.
Van Pesch, V.
Grand'Maison, F.
Fernandez-Bolanos, R.
Lechner-Scott, J.
Spitaleri, D.
Shaygannejad, V.
Iuliano, G.
Granella, F.
Solaro, C.
Prevost, J.
Petersen, T.
Olascoaga, J.
Ramo-Tello, C.
Verheul, F.
McCombe, P.
Slee, M.
Sanchez-Menoyo, J. L.
Cristiano, E.
Ozakbas, S.
Saladino, M. L.
Ampapa, R.
Vucic, S.
Moore, F.
Deri, N.
Alkhaboori, J.
Barnett, M.
Van der Walt, A.
Butzkueven, H.
Kalincik, T.
MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 71 - 73

← 1 2 3 4 5 →